Oral infection of mice with *Salmonella enterica* serovar Typhimurium causes meningitis and infection of the brain

Mark E Wickham¹,⁴, Nat F Brown¹,⁵, John Provias², B Brett Finlay¹ and Brian K Coombes*³

**Background**

*Salmonella* species are Gram-negative, facultative intracellular bacteria that are distributed globally. Two recognized species of *Salmonella* include *S. enterica* and *S. bongori*, with *S. enterica* serovars Typhimurium, Typhi and Enteriditis causing the vast majority of human infections worldwide. Humans are infected with *S. enterica* though contaminated food and water and present with a range of acute symptoms including gastroenteritis, fever, and headache. Although systemic infections with *S. Typhi* are uncommon in developed countries, typhoid remains a significant public health problem in the developing world [1]. Infections with non-typhoidal strains of *Salmonella* are a global burden, with an estimated 1.4 million cases in the United States alone [2].

*Salmonella* meningitis is an uncommon complication of salmonellosis, occurring more frequently in neonates and infants [3,4], although adult cases are reported. While considered rare in the developed world, *Salmonella* is a common cause of enterobacterial meningitis in Africa, Brazil and Thailand [4,5]. Cases in adults of *Salmonella* infection report colonization of the cerebrospinal fluid, fatal brain abscesses caused by intracranial colonization...
of *S. enterica* serotype Typhimurium [6], adult *Salmonella* meningitis [7] and CSF pleocytosis [7]. Mortality rates are typically high, especially in infants where rates have been 60% [8]. Other major issues concerning *Salmonella* meningitis is a high treatment failure rate, high relapse rate and considerable neurological sequelae in those that survive, including mental retardation, cerebral palsy, and visual and hearing impairment [3, 4, 8-11]. The treatment of such complicated cases is made more difficult by the lack of a priori knowledge of the pathogen involved, restrictions in pediatric use of certain antibiotics, the sharp and continued rise in antimicrobial resistance and the proliferation of multi-drug resistant organisms in community settings. The 1970’s to early 1990’s witnessed the emergence of *Salmonella* isolates resistant to the front-line antimicrobial chloramphenicol, as well as cotrimoxazole, ampicillin and amoxicillin [12]. In more contemporary medicine, multi drug-resistant *Salmonella* such as S. Typhimurium strain DT104 is a constant reminder that new anti-infectives against novel targets are in demand. DT104 is commonly resistant to ampicillin, chloramphenicol, florfenicol, streptomycin, spectinomycin, sulfonamides and tetracycline [13] and infections with multi-drug resistant *S. enterica* isolates are associated with higher mortality rates than infection with susceptible strains [14]. This apparent link between drug resistance and virulence is not well understood but deserves considerable attention.

The mechanisms of how *Salmonella* gains access to the CNS and brain are not known. Outstanding questions include (i) how does *Salmonella* disseminate from the intestinal mucosa to the CNS? (ii) how do bacteria gain access to the brain? (iii) what cell types are utilized for transport to the brain and intracellular replication within this compartment? (iv) what role does host genetics and immune repertoire play in this process? Lack of an appropriate animal model has made it difficult to address these questions. An animal model in rabbits of experimental Shigellosis is not well understood but deserves considerable attention.

of *S. enterica* serotype Typhimurium [6], adult *Salmonella* meningitis [7] and CSF pleocytosis [7]. Mortality rates are typically high, especially in infants where rates have been 60% [8]. Other major issues concerning *Salmonella* meningitis is a high treatment failure rate, high relapse rate and considerable neurological sequelae in those that survive, including mental retardation, cerebral palsy, and visual and hearing impairment [3, 4, 8-11]. The treatment of such complicated cases is made more difficult by the lack of a priori knowledge of the pathogen involved, restrictions in pediatric use of certain antibiotics, the sharp and continued rise in antimicrobial resistance and the proliferation of multi-drug resistant organisms in community settings. The 1970’s to early 1990’s witnessed the emergence of *Salmonella* isolates resistant to the front-line antimicrobial chloramphenicol, as well as cotrimoxazole, ampicillin and amoxicillin [12]. In more contemporary medicine, multi drug-resistant *Salmonella* such as S. Typhimurium strain DT104 is a constant reminder that new anti-infectives against novel targets are in demand. DT104 is commonly resistant to ampicillin, chloramphenicol, florfenicol, streptomycin, spectinomycin, sulfonamides and tetracycline [13] and infections with multi-drug resistant *S. enterica* isolates are associated with higher mortality rates than infection with susceptible strains [14]. This apparent link between drug resistance and virulence is not well understood but deserves considerable attention.

The mechanisms of how *Salmonella* gains access to the CNS and brain are not known. Outstanding questions include (i) how does *Salmonella* disseminate from the intestinal mucosa to the CNS? (ii) how do bacteria gain access to the brain? (iii) what cell types are utilized for transport to the brain and intracellular replication within this compartment? (iv) what role does host genetics and immune repertoire play in this process? Lack of an appropriate animal model has made it difficult to address these questions. An animal model in rabbits of experimental Shigellosis is not well understood but deserves considerable attention.

of *S. enterica* serotype Typhimurium [6], adult *Salmonella* meningitis [7] and CSF pleocytosis [7]. Mortality rates are typically high, especially in infants where rates have been 60% [8]. Other major issues concerning *Salmonella* meningitis is a high treatment failure rate, high relapse rate and considerable neurological sequelae in those that survive, including mental retardation, cerebral palsy, and visual and hearing impairment [3, 4, 8-11]. The treatment of such complicated cases is made more difficult by the lack of a priori knowledge of the pathogen involved, restrictions in pediatric use of certain antibiotics, the sharp and continued rise in antimicrobial resistance and the proliferation of multi-drug resistant organisms in community settings. The 1970’s to early 1990’s witnessed the emergence of *Salmonella* isolates resistant to the front-line antimicrobial chloramphenicol, as well as cotrimoxazole, ampicillin and amoxicillin [12]. In more contemporary medicine, multi drug-resistant *Salmonella* such as S. Typhimurium strain DT104 is a constant reminder that new anti-infectives against novel targets are in demand. DT104 is commonly resistant to ampicillin, chloramphenicol, florfenicol, streptomycin, spectinomycin, sulfonamides and tetracycline [13] and infections with multi-drug resistant *S. enterica* isolates are associated with higher mortality rates than infection with susceptible strains [14]. This apparent link between drug resistance and virulence is not well understood but deserves considerable attention.

The mechanisms of how *Salmonella* gains access to the CNS and brain are not known. Outstanding questions include (i) how does *Salmonella* disseminate from the intestinal mucosa to the CNS? (ii) how do bacteria gain access to the brain? (iii) what cell types are utilized for transport to the brain and intracellular replication within this compartment? (iv) what role does host genetics and immune repertoire play in this process? Lack of an appropriate animal model has made it difficult to address these questions. An animal model in rabbits of experimental Shigellosis is not well understood but deserves considerable attention.

of *S. enterica* serotype Typhimurium [6], adult *Salmonella* meningitis [7] and CSF pleocytosis [7]. Mortality rates are typically high, especially in infants where rates have been 60% [8]. Other major issues concerning *Salmonella* meningitis is a high treatment failure rate, high relapse rate and considerable neurological sequelae in those that survive, including mental retardation, cerebral palsy, and visual and hearing impairment [3, 4, 8-11]. The treatment of such complicated cases is made more difficult by the lack of a priori knowledge of the pathogen involved, restrictions in pediatric use of certain antibiotics, the sharp and continued rise in antimicrobial resistance and the proliferation of multi-drug resistant organisms in community settings. The 1970’s to early 1990’s witnessed the emergence of *Salmonella* isolates resistant to the front-line antimicrobial chloramphenicol, as well as cotrimoxazole, ampicillin and amoxicillin [12]. In more contemporary medicine, multi drug-resistant *Salmonella* such as S. Typhimurium strain DT104 is a constant reminder that new anti-infectives against novel targets are in demand. DT104 is commonly resistant to ampicillin, chloramphenicol, florfenicol, streptomycin, spectinomycin, sulfonamides and tetracycline [13] and infections with multi-drug resistant *S. enterica* isolates are associated with higher mortality rates than infection with susceptible strains [14]. This apparent link between drug resistance and virulence is not well understood but deserves considerable attention.

The mechanisms of how *Salmonella* gains access to the CNS and brain are not known. Outstanding questions include (i) how does *Salmonella* disseminate from the intestinal mucosa to the CNS? (ii) how do bacteria gain access to the brain? (iii) what cell types are utilized for transport to the brain and intracellular replication within this compartment? (iv) what role does host genetics and immune repertoire play in this process? Lack of an appropriate animal model has made it difficult to address these questions. An animal model in rabbits of experimental Shigellosis is not well understood but deserves considerable attention.

Methods

**Bacteria and culture conditions**

*Salmonella enterica* serovar Typhimurium strain SL1344 [16] was used throughout this study. Bacteria were routinely cultured in LB broth and on solid LB agar plates containing streptomycin at 50 µg ml⁻¹. Prior to animal infections, bacteria were cultured overnight in LB broth, washed in a buffer containing 0.1 M HEPES (pH 8.0) and 0.9% sodium chloride, and resuspended in the same buffer to ~10⁷ – 10⁹ colony forming units (cfu) per ml.

**Experimental animals**

Experimental animals were female mice between 8 weeks to 12 weeks of age. Five different mouse strains were used in these experiments and include: C57BL/6 (Jackson Laboratories), Balb/c (Jackson Laboratories), 129S6-Slc11a1tm1Mcg (formerly 129/sv Ift/Nramp¹) [17], 129S1/Svlml (Jackson Laboratories), B6.129-Ipp5dtm1Rkh (formerly 129sv/SHIP.1⁻/⁻ F1) [18]. Animals were obtained with full health reports, were deemed to be healthy and free of infection and were housed under specific pathogen free conditions.

**Animal infections and tissue samples**

All animal experiments were conducted as approved by the local Animal Ethics Board and pursuant to guidelines set out by the Canadian Council on Animal Care. Animal infections were carried out by inoculating mice per os using a gavage needle with approximately 10⁶ to 10⁸ wild type *S. enterica* serotype Typhimurium strain SL1344 in a 0.1 ml volume. Infected animals were examined twice daily for signs of terminal morbidity and animals that had become moribund or that exhibited a balance defect were euthanised by cervical dislocation. At necropsy the brain was removed, dissected into right and left hemispheres with one hemisphere processed for pathology and the other placed in 1 ml of sterile phosphate buffered saline. This latter sample was homogenized in a tissue homogenizer (Polytron, Kinematica) and the homogenate was diluted in sterile PBS and plated on solid LB agar containing streptomycin to enumerate *S. Typhimurium* cfu. Bacterial load was expressed as cfu/organ.

**Pathology scoring**

For pathologic scoring, brain tissues were fixed in 2% paraformaldehyde in routine fashion [19] and sectioned using a gavage needle with approximately 10⁶ to 10⁸ wild type *S. enterica* serotype Typhimurium cfu. Bacterial load was expressed as cfu/organ.
esterase to identify mast cells. A neuropathologist examined all brain sections blindly. The degree of inflammation was scored on a 0 to 4+ scale, 0 representing no inflammation and 4+ representing involvement of the entire contour of the sub-arachnoid space of the section.

Results

**Observations on infected mice**

Our studies on *Salmonella enterica* pathogenesis involve infection of the mouse in order to examine bacterial virulence factors that are essential during discrete stages of infection. During the acute phase of infection, mice develop overt signs of infection (hunched posture, reduced movement, loss of body weight, piloerection). During the course of these studies over several years, we became interested in a proportion of mice that developed a neurological abnormality with balance defect following infection. These mice exhibited an exaggerated lean to one side of the body and longitudinal spinning and rotary motion as the most prominent manifestation of infection. Rolling occurred in either direction (however only unidirectional movement was observed for any given mouse) ranging from intermittent rolling through to constant rolling (Figure 1 and Additional file 1). Neurological deficits were not unique to one particular strain of mouse, as we observed this behaviour in five distinct mouse lines including wild type C57BL/6, wild type BALB/c, 129S1/SvImJ, 129S6-Svl11a1tm1^Inpp5dtm1^B6, and B6.129-Inpp5dtm1^B6.

**Examination of bacterial load in infected mice**

The observed neurological deficits following infection lead us to speculate that an intracranial infection with *Salmonella* was taking place in affected mice. To examine the dissemination of *S. Typhimurium* in mice exhibiting rolling behavior, bacterial load was examined in both rolling and non-rolling infected mice. Brains of mice exhibiting neurological deficit had significantly higher bacterial loads (mean, 2.66 ± 0.66 × 10^6 cfu/organ) than infected mice without overt signs of neurological deficit (mean, 4.21 ± 1.72 × 10^3 cfu/organ) (P = 0.0002, Mann Whitney) (Figure 1). Whereas some non-rolling mice had no detectable cfu in the brain (approximately 10–20% of animals), this was never the case for infected mice that had developed neurological deficits.

**Pathologic examination of mouse brains**

The finding that a proportion of mice developed neurological deficits following oral infection with *S. Typhimurium* and that these mice had a significantly greater bacterial load in the brain compared to non-affected mice lead us to test whether mice developed meningitis following infection. Mouse brains that were processed for histopathology were randomized and coded and scored by a neuropathologist who was blinded to the treatment history and clinical outcome of the mouse. The principal clinical finding was the presence of patchy meningitis confined to the sub-arachnoid space in all mice with neurological deficit (see Table 1). The meningitis was composed of a mixture of acute and chronic inflammatory cells, chiefly neutrophils and macrophages. In general the meningitis was consistent with a sub-acute time frame reflecting a process of a few days to one week in duration. The inflammation was non-necrotizing and no granulomas were present. The degree of inflammation was scored on a 0 to 4+ scale, 0 representing no inflammation and 4+ representing involvement of the entire contour of the sub-arachnoid space of the section (data summarized in Table 1). Some of the brains had thrombosed sub-arachnoid vessels in areas of meningitis, however none of the cases had any cerebral infarction or encephalitis. One of the cases with more intense meningitis also had a ventriculitis...
(Figure 2). There was no obvious correlation between development of meningitis and bacterial load in other systemic sites of infection including the liver and spleen. Bacterial load in these sites is typically variable in infected mice and ranged from \( \sim 1 \times 10^4 \) to \( 5 \times 10^6 \) cfu per organ (data not shown) regardless of the clinical diagnosis of the animal.

**Discussion**

The occurrence of meningitis caused by serovars of *Salmonella enterica* is relatively rare in developed countries [20], but in countries such as Africa, Thailand, and Brazil [3,5], it is a common cause of Gram-negative bacterial meningitis in infants with high mortality rates being reported. A study of infant *Salmonella* meningitis in Kuala Lumpur reported an 18% fatality rate with surviving infants experiencing considerable long-term neurological dysfunction (57%) and high relapse rates (38%) [3]. Although *Salmonella* meningitis is a rare complication of adult salmonellosis, the increased incidence of *Salmonella* bacteremia in HIV-infected patients [21,22], may expose such individuals to increased risk for more disseminated and protracted infections. Importantly, alarming increases in multi-drug resistance *Salmonella enterica* may be a harbinger for more virulent strains of *Salmonella* with increased invasive potential.

The ability of *S. Typhimurium* to infect the mouse brain was related to functional virulence loci including the type III secretion systems encoded in chromosomal genomic islands. In our studies over several years, infection of C57BL/6 mice with *S. Typhimurium* containing mutations in either of these secretion systems was never found to produce neurological deficits (over 1000 animals, data not shown) and mutant bacteria could not be recovered from the brains of representative infected mice (10 animals, data not shown). Neurological deficits were not unique to one particular strain of mouse, as we observed this behavior in five different mouse lines including wild type C57BL/6, wild type BALB/c, 129S1/SvImJ, 129S6-

### Table 1: Clinical Summary

| Mouse | Treatment | Behaviour | Clinical Features | Meningitis score | Genetic background |
|-------|-----------|-----------|------------------|------------------|-------------------|
| 1     | uninfected| non-rolling| normal           | 0                | C57BL/6           |
| 2     | infected  | non-rolling| normal           | 0                | C57BL/6           |
| 3     | infected  | rolling    | meningitis, thrombosis | 1+   | Balb/c           |
| 4<sup>b</sup> | infected | rolling    | meningitis       | 2+   | C57BL/6           |
| 5     | infected  | rolling    | meningitis, thrombosis | 0.5+ | Balb/c           |
| 6     | infected  | rolling    | meningitis, ventriculitis | 2+ | Balb/c           |
| 7     | infected  | rolling    | meningitis       | 1+  | 129S6-Slc11a1tm1Mcg |

<sup>a</sup> slides were scored with the observer blinded to mouse history

<sup>b</sup> mouse shown in Additional file 1

---

**Figure 2**

**Histopathology of infected brain sections.** (A, B) Coronal sections of brain with sub-arachnoid meningeal inflammation (arrowheads). Macrophages are the predominant cellular infiltrate in these fields. Thrombosed sub-arachnoid vessels are marked with arrows. H&E; mag, 100×. (C) Area of ventriculitis seen in the brain of mouse #6. H&E; mag, 200×.
Scl1a1tm1Mcg, and B6.129-Inpp5dtm1Rkh. Much work has investigated the genetic factors in mice involved in resistance to S. Typhimurium infection [23]. These efforts have revealed a critical role for the Scl1a1 gene (formally Nramp1) in early innate resistance to Salmonella infection [17]. We note that 4 out of the 5 mouse strains used in our work carry a non-functional mutant allele of Scl1a1 (C57BL/6, BALB/c, 129S6-Scl1a1tm1Mcg, and B6.129-Inpp5dtm1Rkh). While we did observe neurological deficits in a mouse line that normally resists lethal infection due to a wild type Scl1a1 allele (129S1/Sv1m1), our current sample size does not permit detailed conclusions to be drawn regarding the impact of Scl1a1 status on meningitis development. Thus, it is possible that both bacterial and host genetic factors are involved in infection of the brain and the development of meningitis. Further work using larger sample sizes and controls could address these issues. We cannot exclude hemiparesis in mice with neurological deficits and the potential involvement in this behaviour of the vestibular system will require additional investigation.

The ability of Salmonella to disseminate naturally to the brain in several mouse lines allows the use of the vast array of transgenic and knockout mouse strains to address the host genetic factors influencing CNS dissemination including the mode of bacterial transport from intestinal sites to systemic sites of infection, the role of various immune cells in the trafficking of intracellular salmonellae to the CNS and brain, and the role of various immune cell migration factors in this process. We suggest that the mouse model of Salmonella typhoid could represent a useful tool in which to investigate basic mechanisms of CNS infiltration and brain infection following oral ingestion of Salmonella. This model could also be exploited to examine the efficacy of investigational medicines (vaccines, antibacterials, and host genetic factors, and BKC performed research, MEW, JP, and BKC analyzed data, MEW, NFB, JP, BF, and BKC wrote the paper. All authors read and approved the final manuscript.

Additional material

Acknowledgements
The authors wish to thank Jennifer Bishop, Guntram Grassl, Bryan Coburn and Yanet Valdez for contributing mice to this study. MEW was a CIHR and MSFHR postdoctoral fellow and NFB was a postdoctoral fellow of the MSFHR. This work was supported by grants to BF from the Canadian Institutes of Health Research (CIHR) and to BKC from the Public Health Agency of Canada and the CIHR.

References
1. Huang DB, DuPont HL: Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis 2005, 5(6):341-348.
2. Voetsch AC, Van Gilder TJ, Angulo FJ, Farley MM, Shallow S, Marcus R, Cieslak PR, Deneen VC, Tyson RV: FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis 2004, 38 Suppl 3:S127-34.
3. Lee WS, Puthucheary SD, Omar A: Salmonella meningitis and its complications in infants. J Paediatr Child Health 1999, 35(4):379-382.
4. Chotpitayasunondh T: Bacterial meningitis in children: etiology and clinical features, an 11-year review of 618 cases. The Southeast Asian Journal of tropical medicine and public health 1994, 25(1):107-115.
5. Bryan JP, de Silva HR, Tavares A, Rocha H, Scheld WM: Etiology and mortality of bacterial meningitis in northeastern Brazil. Reviews of infectious diseases 1990, 12(1):128-135.
6. Chadwick D, Mitra T, Sioth Y: Salmonella typhimurium brain abscess. The Lancet 2004, 363(9413):947.
7. Karim M, Islam N: Salmonella meningitis: report of three cases in adults and literature review. Infection 2002, 30(2):104-108.

infection of mice with S. Typhimurium is an accessible model in which to study the host and bacterial determinants that lead to dissemination and progression of infection from the gastrointestinal tract to the brain. We propose that this model has utility for testing new antibacterial chemotherapies to treat complicated, life-threatening Salmonella infections.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
MEW, JP, and BKC designed research, MEW, NFB, JP, and BKC performed research, MEW, JP, and BKC analyzed data, MEW, NFB, JP, BB, and BKC wrote the paper. All authors read and approved the final manuscript.

Conclusion
Oval infection of mice with Salmonella enterica serovar Typhimurium might represent a useful model in which to study the dissemination of a pathogen from the natural route of infection to the brain. Infection of the brain is followed by meningitis and a neurological deficit in a proportion of infected animals. Because more virulent strains of Salmonella are commonly associated with antibiotic resistance, the continued global epidemic spread of multi-drug resistant Salmonella isolates in human and animal medicine (such as S. Typhimurium DT104) presents a serious public health issue. Drug resistance in such isolates challenges our ability to treat life-threatening cases of salmonellosis, especially in infants and children. Oral

Additional File 1
Supplementary video 1. Movie showing rolling behavior of a C57BL/6 mouse infected with Salmonella enterica serovar Typhimurium at day 9 post-infection. Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2334-7-65-S1.mov]
8. Drevets DA, Leenen PJ, Greenfield RA: *Invasion of the central nervous system by intracellular bacteria*. Clin Microbiol Rev 2004, 17(2):323-347.

9. Appelbaum PC, Scragg J: *Salmonella meningitis in infants*. Lancet 1977, 1(8020):1052-1053.

10. Denis F, Badiane S, Chiron JP, Sow A, Mar ID: *Salmonella meningitis in infants*. Lancet 1977, 1(8017):910.

11. Kavliotis J, Tsiaousi A, Papavasiliou D, Kansouzidou A: *Nontyphoid Salmonella meningitis*. Scand J Infect Dis 1994, 26(4):403-405.

12. Bhan MK, Bahl R, Bhatnagar S: *Typhoid and paratyphoid fever*. Lancet 2005, 366(9487):749-762.

13. Helms M, Ebeling S, Molbak K: *International Salmonella Typhimurium DT104 infections, 1992-2001*. Emerg Infect Dis 2005, 11(6):859-867.

14. Helms M, Vastrup P, Gerner-Smidt P, Molbak K: *Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium*. Emerg Infect Dis 2002, 8(5):490-495.

15. Bryan JP, Scheld WM: *Therapy of experimental meningitis due to Salmonella enteritidis*. Antimicrobial agents and chemotherapy 1992, 36(5):949-954.

16. Wray C, Szoka WJ: *Experimental Salmonella typhimurium infection in calves*. Res Vet Sci 1978, 25(2):139-143.

17. Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, Malo D, Skamene E, Olivier M, Jothy S, Goss P: *The Icy/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene*. J Exp Med 1995, 182(3):655-666.

18. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappell SM, Borowski A, Jirik F, Krystal G, Humphries RK: *Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span*. Genes Dev 1998, 12(11):1610-1620.

19. Coombes BK, Coburn BA, Potter AA, Gomis S, Mirakhor K, Li Y, Finlay BB: *Analysis of the contribution of Salmonella pathogenicity islands 1 and 2 to enteric disease progression using a novel bovine ileal loop model and a murine model of infectious enterocolitis*. Infect Immun 2005, 73(11):7161-7169.

20. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, Perkins BA: *Bacterial meningitis in the United States in 1995. Active Surveillance Team*. N Engl J Med 1997, 337(14):970-976.

21. Leonard MK, Murrow JR, Jurado R, Gaynes R: *Salmonella meningitis in adults infected with HIV: case report and review of the literature*. Am J Med Sci 2002, 323(5):266-268.

22. Celum CL, Chaissen RE, Rutherford GW, Barnhart JL, Echenberg DF: *Incidence of salmonellosis in patients with AIDS*. J Infect Dis 1987, 156(6):998-1002.

23. Roy MF, Malo D: *Genetic regulation of host responses to Salmonella infection in mice*. Genes Immun 2002, 3(7):381-393.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/7/65/prepub